Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0451641 (urolithiasis)
 3,973 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Chondroitin polysulfate (CPS) have inhibitory activity on stone formation of calcium oxalate. This study compared the inhibitory effect of three CPS (CPS S-I, CPS S-II, CPS S-III) with sodium pentosan polysulfate (SPP) and chondroitin sulfate (CS). Crystal growth inhibition was measured in a seeded crystal growth system with 14C-oxalate, and CPS S-I and CPS S-II were the most active substances inhibiting crystal growth. Since CPS S-II and CPS S-III had remarkable hemorrhagic adverse effect, these two substances were excluded from the following study. The study of administration of the rest of the substances (CPS S-I, SPP, CS) to rats revealed that CPS S-I highly inhibited formation of stone in kidney. About 65 percent of CPS S-I administered subcutaneously was excreted in 24 hours urine. Therefore it may be of value to study clinical usefulness of CPS S-I for treatment of patient with urolithiasis.
 ...
PMID:[A study of inhibitory effect of chondroitin polysulfate on stone formation of calcium oxalate]. 143 67

The effect of chondroitin sulfate upon the growth of calcium oxalate crystals was measured in vivo by using an experimental model in rats. Adult male Wistar rats were treated by chronic i.p. injections of chondroitin sulfate solutions (1, 5 or 10 mg in 0.3 ml of saline, every 2 days). This treatment led to a dose-dependent increase in the urinary chondroitin sulfate concentration. Urolithiasis was induced by the introduction of a calcium oxalate seed into the bladder of the animals. Urine samples were collected and the calculi formed were removed after 42 days. The chondroitin sulfate concentration have decreased in the lithiasic urines, as compared to controls and higher chondroitin sulfate doses correlated with larger calculi. The presence of chondroitin sulfate in the matrices of stones obtained from chondroitin sulfate-treated animals suggested that there was some adsorption of chondroitin sulfate on to the growth sites of the calcium oxalate crystals. In contrast to the chondroitin sulfate effect observed in vitro, which inhibits the growth of calcium oxalate crystals, our results suggest that in vivo chondroitin sulfate promotes the growth of stones in the urinary tract.
 ...
PMID:Possible role for chondroitin sulfate in urolithiasis: in vivo studies in an experimental model. 163 45

Glycosaminoglycans (GAG) are polysaccharide chains composed of repeating disaccharides of identical composition. Little is known about the mechanism of their excretion, but there is no doubt that urinary GAGs are degradation products of high molecular weight proteoglycans. Renal excretion takes place chiefly as glomerular filtration, and tubular reabsorption or secretion has not been demonstrated. Differences in the literature comparing GAG excretion in urolithiasis patients and healthy subjects are mainly attributable to methods of analysis and noncomparability of the investigation conditions. We found no differences between the two groups in several series. It is interesting to note that GAG excretion in men is significantly higher than in women, that a circadian rhythm of GAG concentration and excretion occurs in healthy subjects on a standardized diet, and that values are raised postprandially and at night. Seasonal course of GAG excretion curves is almost synchronous for men and women, irrespective of the absolute values, and GAG excretion in the spring and summer significantly exceeds that in winter months by up to 50%. All crystallization models cited demonstrate that GAG reduce the risk of calcium oxalate stone formation. Inhibitors of crystal growth and aggregation act by blocking the growth sites. Inhibition of calcium oxalate crystallization is also attributed to direct binding of calcium to GAG. In the presence of urate ions, and favorable pH, the ability of chondroitin sulfate C to bind calcium may be impaired by as much as 31%. These measurements support the concept that urate ions interact with GAG in urine.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Significance of glycosaminoglycans for the formation of calcium oxalate stones. 200 9

There is evidence suggesting that glycosaminoglycans (GAG) are potent inhibitors of growth and aggregation of calcium oxalate crystals in vitro. This finding raises the possibility that the urinary GAG could play an inhibitory role in the urolithiasis. To investigate this hypothesis, a study on the urinary excretion of GAG in normal and stone forming adults and children was undertaken. Different methods were compared, and the best results were obtained when the GAG were measured by densitometry after agarose gel electrophoresis. Although the GAG concentration was increased in the morning urine compared to the 24-hour urine samples, and in males compared to females, the GAG/creatinine ratio was independent of period of urine collection and of sex. So, it was advantageous to express the amounts of urinary GAG as mg/g of creatinine. Children excreted more GAG than adults, with a higher proportion of chondroitin sulfate. We have shown that the stone forming subjects, both adults and children, excreted lower levels of urinary GAG as compared to normal subjects, independently of the metabolic disorder. The proportions between chondroitin sulfate and heparan sulfate and the structures of these GAG were unaltered in the stone formers. These results indicate that there is a definite difference in terms of levels of GAG between normal and stone forming urines, and suggest a correlation between the urinary GAG concentration and urolithiasis.
 ...
PMID:Urinary excretion of glycosaminoglycans in normal and stone forming subjects. 260 Dec 52

In this study, 17 kidney tissue specimens and 29 renal stones were obtained from patients with urolithiasis. Control kidney specimens were dissected from 7 individuals not suffering from urolithiasis. The tissue specimens were fixed with 1% cetylpiridinium chloride (CPC) in 10% formalin (for 24 hours at room temperature). Then the kidney tissue specimens were embedded in paraffin and stained with hematoxylin-eosin for general observation as well as histochemically for demonstration of complex carbohydrates. Also, stone specimens were embedded in epon and thin sections made by the mineral polishing specimen preparation, and stained along with the kidney tissues. For identifying individual acidic and neutral carbohydrates, the enzyme digestion was performed for some tissue sections prior to histochemical staining. The stone-forming kidney tissues, normal kidney tissues and urinary stones (calcium oxalate, mixed, struvite) contained some glycosaminoglycans and neutral glycoproteins, but uric acid stones and cystine stones did not. The results of digestion with enzymes indicated that calcium oxalate stone-forming kidney tissue contains heparitin (heparan) sulfate; mixed stone-forming tissue contains sialic acid, hyaluronic acid, chondroitin sulfate A, B, C and heparitin (heparan) sulfate; struvite stone-forming tissue contains sialic acid, hyaluronic acid, chondroitin sulfate A, C and heparitin (heparan) sulfate; and cystine stone-forming tissue contains sialic acid, chondroitin sulfate A, C and heparitin (heparan) sulfate. The stone organic matrix is classified into the amorphous and stratiform types. The amorphous type matrix contains chondroitin sulfate A, B, C and heparitin (heparan) sulfate, and the stratiform type matrix also contains sialic acid and hyaluronic acid. The stone-forming kidney tissues, normal kidney tissues and stones (calcium oxalate, mixed, struvite) contain an appreciable amount of alpha-D-glucose, alpha-D-mannose and beta-D-galactose, but the uric acid stones and cystine stones do not contain sugar residues. Since the specific glycosaminoglycan composition differed for kidneys of different mineral content and stones of different morphological type, we believe that some glycosaminoglycans in kidneys and amorphous type matrix might play the role of a nucleating agent, and that a stratiform type matrix encourages stone enlargement.
 ...
PMID:[Studies on urolithiasis. The histochemistry of the kidney tissues and stones from patients with urolithiasis]. 293 57

A simple and rapid technique for the determination of oxalate in urine by ion chromatography has been described. Although there is difficulty in separating the oxalate peak from the sulfate peak on the conductivity chromatogram of unprocessed urine, it is possible to eliminate the sulfate peak by the addition of barium chloride to the urine. Using this technique, the author has estimated the urinary oxalate in 33 urolithiasis patients and in 40 non-urolithiasis patients. The means of 50 urinary oxalate determinations in 33 urolithiasis patients and of 42 urinary oxalate determinations in 40 non-urolithiasis patients were 21.5 +/- 11.4 and 19.5 +/- 13.0 mg/gCr, respectively. Of the 33 urolithiasis patients, 17 were calcium stone formers and 6 were non-calcium stone formers whose stones had been analyzed by infrared spectrometry, and the mean urinary oxalate values were 19.4 +/- 6.9 and 21.3 +/- 8.2 mg/gCr, respectively. The urinary oxalate was significantly higher in children under the age of 10 years.
 ...
PMID:A simple ion--chromatographic method for determination of urinary oxalate. 404 4

The aim of this study was to examine the effect of sodium pentosan polysulfate (SPP) in an undiluted urine system and to study its relative affinity to calcium oxalate (CaOx) crystals in the presence or absence of heparan sulfate (HS). CaOx crystals were induced with an overload of oxalate above the metastable limit in spun and filtered urine (SF) and ultrafiltered urine (UF). Then, the crystals were dissolved with EDTA (ethylenediaminetetraacetic acid), electrodialysed and lyophilized. The polyanions, HS or SPP were added to the UF prior to the addition of oxalate. Polyanions in crystal matrices were examined by cellulose acetate electrophoresis. Crystal volume and size were suppressed according to the increase of the concentration of SPP when compared with those of the UF. Scanning electron microscopy (SEM) showed marked aggregation of the crystals in the UF and no aggregation in the presence of SPP. HS was the only polyanion found in CaOx crystals formed after overload of oxalate in SF. Crystals formed in UF did not contain any polyanions. When SPP was added to UF, SPP appeared in the crystal matrix in accordance with its concentration. Once HS in physiological concentration was added to the UF containing SPP, HS and SPP obtained from crystals were strongly stained with Alcian blue in electrophoretic study, where SPP is stained stronger than HS. These results suggest that SPP strongly binds to CaOx crystals as well as HS and that HS and SPP competitively bind to the crystal, then, as a result, they are incorporated into the crystals. The fact that SPP suppressed the aggregation of CaOx crystals in undiluted urine showed the possibility that SPP might be one of the useful drugs for preventing CaOx urolithiasis.
 ...
PMID:Analysis of glycosaminoglycans induced in newly formed calcium oxalate crystals using an undiluted urine system. 881 90

To investigate the risk for the development of urolithiasis in 30 children with urolithiasis, 36 children with isolated hematuria, and 15 healthy control children, 24-h urinary excretion of calcium, sodium, oxalate, citrate, sulfate, phosphate, magnesium, urate, chloride, ammonium, and glycosaminoglycans was determined and urine saturation for calcium oxalate was calculated with the computer program EQUIL 2. Compared with controls, children with urolithiasis had significantly increased calcium excretion, oxalate excretion, and urine saturation, whereas children with isolated hematuria had significantly increased calcium excretion only. The best estimation of the relative risk of urolithiasis can be made after urine saturation, using logistic regression. The percentage of patients correctly classified after urine saturation is 85.41% in comparison with 80.95% and 73.81% when the estimation was done by calcium excretion and oxalate excretion, respectively. Using the breakpoint value of 4.29 for urine saturation, it was possible to separate children with increased risk of urolithiasis development from the group of children with isolated hematuria.
 ...
PMID:Determination of urine saturation with computer program EQUIL 2 as a method for estimation of the risk of urolithiasis. 969 74

The factors precipitating clinically active calcium oxalate (CaOx) urolithiasis are not known. This study examined the relationships between urinary proteins that inhibit CaOx crystallization in vitro and the incidence of CaOx urolithiasis. The first hypothesis is that levels of urinary CaOx crystallization inhibitors differ between clinically active stone formers (SFs) and normal individuals. The second hypothesis is that lower levels of urinary CaOx crystallization inhibitors contribute to the two- to threefold greater incidence of CaOx urolithiasis in males compared with females. These hypotheses were derived from previous observations on the expression of urinary inter-alpha-trypsin inhibitor trimer (IalphaTI-trimer) in normal and stone-forming individuals. The proteins of void urine samples from normal volunteers (24 males, 19 females) and CaOx-SFs (26 males, 16 females) were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Immunoreactive IalphaTI-trimer, osteopontin, and prothrombin were detected by immunoblot plus enhanced chemiluminescence; the relative densities of the bands were then determined. With the exception of IalphaTI-trimer (P: </= 0.026, approximately twofold), there was no difference in the relative densities of CaOx crystallization inhibitors in the urine of normal and CaOx stone-forming individuals. Thus, there does not appear to be a generalized increase or decrease in levels of CaOx crystallization inhibitory proteins between normal and CaOx stone-forming individuals. The relative density of IalphaTI-trimer was approximately threefold greater in females than in males (P: </= 0.001). Differences in the relative densities of the other CaOx crystallization inhibitors were small and of questionable physiological importance. These data do not support the hypothesis that males have a greater incidence of CaOx urolithiasis because of a generalized decrease in urinary CaOx crystallization inhibitory protein levels.
 ...
PMID:Expression of proteins that inhibit calcium oxalate crystallization in vitro in the urine of normal and stone-forming individuals. 1113 74

Urinary macromolecules, especially glycosaminoglycans (GAGs), have attracted great interest as promising inhibitors of urinary stone formation. As an analogue of GAGs, low-molecular-weight polyguluronate sulfate (LPGS) with strong polyanionic nature was prepared by chemical modification of brown algae extract. The effects of LPGS both on ethylene glycol-induced nephrolithiasis and Zinc disc implant-induced urinary bladder stone formation in Wistar rats were evaluated, and its acute toxicity in Kunming mice and Wistar rats were also investigated. The contents of renal oxalate and calcium in ethylene glycol-induced nephrolithiasic rats were decreased significantly from 5.01 +/- 0.96 to 3.26 +/- 1.31 mumol/g kidney (P < 0.01) and 20.11 +/- 4.60 to 11.83 +/- 3.54 mumol/g kidney (P < 0.01), respectively, after oral administration of LPGS at dose-level of 100 mg/kg. The renal crystal depositions and histopathological changes were reduced also. The formation of zinc disc implant-induced urinary bladder stones in rats was inhibited considerably after oral administration of LPGS at dose-levels of 50 mg/kg (P < 0.05) and 100 mg/kg (P < 0.01). The intravenous LD(50) and the oral maximum tolerance value of LPGS in mice are 6.29 and 25 g/kg, and in rats are 2.25 and 10 g/kg, respectively. These data show that LPGS has significant prevention effects both on nephrolithiasis and urinary bladder stone formation in rats, and negligible oral toxicity both in mice and rats. LPGS is a safe and promising drug candidate for the prevention of urolithiasis.
 ...
PMID:Effects of low-molecular-weight polyguluronate sulfate on experimental urolithiasis in rats. 1792 6


1 2 3 Next >>